다낭성 난소 증후군(PCOS) 치료 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the polycystic ovarian syndrome treatment market size was valued at USD 5.08 billion in 2025 and estimated to grow from USD 5.39 billion in 2026 to reach USD 7.24 billion by 2031, at a CAGR of 6.07% during the forecast period (2026-2031).

This report is Segmented by Treatment (Drug Class and Surgery), Patient Need (Fertility Management, and More), Route of Administration (Oral, and More), Distribution Channel (Hospital Pharmacies, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Polycystic Ovarian Syndrome Treatment Market Trends and Insights

Rising Global Burden of Polycystic Ovary Syndrome

New epidemiological surveys report prevalence as high as 17.40% among urban women aged 18-35, far above earlier global estimates of 8-13%. The Global Burden of Disease 2021 update logged an 89% rise in diagnosed cases between 1990 and 2021, with disability-adjusted life years up 87%. Providers now routinely screen adolescents presenting with obesity or irregular cycles, capturing milder phenotypes that once went unrecorded. Economic drag is no longer limited to infertility treatments; downstream diabetes, cardiovascular events, and lost productivity place mounting strain on health budgets. As a result, ministries of health in India, Saudi Arabia, and the Philippines are embedding PCOS modules into national non-communicable disease programs, anchoring long-term demand for integrated solutions.

Growing Focus on Women's Metabolic Health

Insulin resistance afflicts at least half of all PCOS patients, prompting a pivot from purely reproductive goals to long-run cardiometabolic safeguarding. Semaglutide 2.4 mg produced 12.3% mean weight loss versus 5.7% with metformin in a 48-week head-to-head study, while also curbing free testosterone by 34%. Three-in-one incretin agonists that stimulate GLP-1, GIP, and glucagon pathways are in Phase II, promising additive effects on visceral fat and ovulatory recovery. Payers in Germany and Australia recently classified PCOS as a high-risk pre-diabetes state, green-lighting earlier metabolic pharmacotherapy.

Lack of PCOS-Specific FDA-Approved Therapeutics

With no drug formally labelled for PCOS, clinicians lean on diabetes, contraceptive, and weight-loss indications, setting up cumbersome prior-authorization hurdles: 83% of US patients confront at least one rejection before receiving GLP-1 therapy. Trial design is complicated by heterogeneous phenotypes, making agreement on composite endpoints slow. Although recent FDA draft guidance provides clarity, full approvals remain several years away, elongating commercialization cycles and tempering short-term revenue capture.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion of Fertility Services and Assisted-Reproduction Clinics
2. Advances in Endocrine and Metabolic Drug Development
3. Safety Concerns With Long-Term Hormonal Therapy

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Drugs captured 56.92% of the Polycystic Ovarian Syndrome Treatment market in 2025, anchoring revenue through high prescription renewal rates and broad insurance familiarity. Combined oral contraceptives, metformin, and the first wave of GLP-1s dominate formularies, with selective serotonin-reuptake inhibitors addressing comorbid anxiety and depression in 68% of patients. Pipeline diversity is widening as biotechs test androgen receptor degraders and granulosa-cell modulators. Competitive intensity should rise once next-generation incretin tri-agonists, now in Phase II, publish ovulation endpoints.

Surgical and device-based interventions are expanding at an 8.43% CAGR, albeit from a smaller base, driven by minimally invasive ovarian drilling and emerging electrothermal ablation platforms. The REBALANCE study investigates May Health's catheter-based device, which applies sub-second radiofrequency bursts under ultrasound guidance, potentially reducing adhesion risk versus laparoscopy. Should 12-month ovulation data hold, payors may reposition device therapy ahead of costly repeat pharmacological cycles in clomiphene-resistant cohorts, reshaping reimbursement hierarchies.

Fertility management commanded 54.88% of patient expenditure in 2025, reflecting the high share of anovulatory infertility attributable to PCOS and strong demand for ovulation-induction agents and assisted reproduction services. Live-birth rates surpass 60% in women under 35 when individualized stimulation protocols incorporate insulin sensitizers and time-luteal support precisely. Clinics now market bundled packages that weave endocrinology, nutrition, and embryo services, elongating revenue per patient.

Demand for cosmetic and hyperandrogenism relief-covering hirsutism, acne, alopecia-ranks second and will grow fastest at 8.69% CAGR. Patient-reported outcomes reveal sustained distress even in normo-ovulatory phenotypes, spurring uptake of topical anti-androgens, diode-laser hair systems, and dermatology teleconsults. Digital health platforms embed photo-tracking and hormonal dashboards, giving users measurable progress indicators and driving subscription retention beyond fertility-centric windows.

Complete Report Scope:

• By Treatment
  • Drug Class
    • Hormonal Contraceptives
    • Insulin-Sensitizing Agents
    • Anti-Depressants
    • Anti-Obesity Agents
    • Other Drug Classes
  • Surgery
    • Ovarian Wedge Resection
    • Laparoscopic Ovarian Drilling
    • Other Surgeries
• By Patient Need
  • Fertility Management
  • Metabolic / Weight Management
  • Cosmetic / Hyper-androgenism Relief
• By Route of Administration
  • Oral
  • Injectable
  • Implantable
  • Transdermal
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies & DTC Platforms
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America led with 41.98% share in 2025, fueled by broad insurance coverage for diagnostic workups, mature fertility infrastructure, and extensive clinical-trial activity. The United States accounted for more than 80% of regional revenue, although prior-authorization hurdles delay GLP-1 starts by a median 37 days. Canada's recent approval of fezolinetant for vasomotor symptoms signals a regulator receptive to menopausal and metabolic endpoints, setting a precedent for future PCOS-label applications.

Asia-Pacific is the fastest-growing territory at 7.44% CAGR, underpinned by higher urban prevalence, rising disposable income, and large unmet fertility demand. Indian metropolitan studies document 17.40% prevalence in women aged 20-29, spurring federal health centers to adopt universal PCOS screening during antenatal visits. Regulatory harmonization under ASEAN's Pharmaceutical Product Working Group eases cross-border drug launches, while China's relaxation of the three-child policy expands reproductive-service enrolments.

Europe delivers steady mid-single-digit gains thanks to universal health coverage and robust specialist networks. National frameworks increasingly reimburse metabolic interventions earlier in the disease course, with Germany's statutory insurers adding semaglutide to the obesity benefit list for PCOS in 2025. Real-world data from Scandinavian registries feed safety authorities, accelerating label updates for combination therapies.

The Middle East and Africa display sharp prevalence spikes-age-standardized rates rose 37.9% between 1990 and 2019-yet therapeutic uptake remains limited by fragmented reimbursement and specialist scarcity. Pilot tele-endocrinology programs in Saudi Arabia reduce travel times by 60%, indicating digital care may leapfrog facility shortages. South American awareness is climbing: Brazilian cardiovascular societies now classify PCOS as a risk enhancer, prompting lipid-panel reimbursement and metabolic screening.

1. Abbott Laboratories
2. Abbvie
3. Addex Therapeutics
4. AstraZeneca
5. Bayer
6. BIOCAD
7. Bristol-Myers Squibb
8. Crinetics Pharmaceuticals
9. EffRx Inc.
10. Ferring Pharmaceuticals
11. Johnson & Johnson
12. Merck
13. Mylan
14. Neurocrine Biosciences
15. Novartis
16. Pfizer
17. Sanofi
18. Shire PLC (Takeda)
19. Takeda Pharmaceuticals
20. Teva Pharmaceutical Industries
21. Organon
22. Gedeon Richter PLC
23. Novo Nordisk

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Global Burden of Polycystic Ovary Syndrome
  • 4.2.2 Increasing Adoption of Hormonal Contraceptives For Symptom Management
  • 4.2.3 Growing Focus on Women's Metabolic Health
  • 4.2.4 Expansion of Fertility Services And Assisted Reproduction Clinics
  • 4.2.5 Advances in Endocrine and Metabolic Drug Development
  • 4.2.6 Government-Led Awareness and Screening Programs
• 4.3 Market Restraints
  • 4.3.1 Lack of Pcos-Specific Fda Approved Therapeutics
  • 4.3.2 Safety Concerns With Long-Term Hormonal Therapy
  • 4.3.3 High Out-Of-Pocket Costs For Infertility Treatments
  • 4.3.4 Limited Access to Specialist Care in Emerging Markets
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Treatment
  • 5.1.1 Drug Class
    • 5.1.1.1 Hormonal Contraceptives
    • 5.1.1.2 Insulin-Sensitizing Agents
    • 5.1.1.3 Anti-Depressants
    • 5.1.1.4 Anti-Obesity Agents
    • 5.1.1.5 Other Drug Classes
  • 5.1.2 Surgery
    • 5.1.2.1 Ovarian Wedge Resection
    • 5.1.2.2 Laparoscopic Ovarian Drilling
    • 5.1.2.3 Other Surgeries
• 5.2 By Patient Need
  • 5.2.1 Fertility Management
  • 5.2.2 Metabolic / Weight Management
  • 5.2.3 Cosmetic / Hyper-androgenism Relief
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Injectable
  • 5.3.3 Implantable
  • 5.3.4 Transdermal
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 Online Pharmacies & DTC Platforms
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 AbbVie Plc
  • 6.3.3 Addex Therapeutics Ltd.
  • 6.3.4 AstraZeneca PLC
  • 6.3.5 Bayer AG
  • 6.3.6 BIOCAD
  • 6.3.7 Bristol-Myers Squibb Co.
  • 6.3.8 Crinetics Pharmaceuticals
  • 6.3.9 EffRx Inc.
  • 6.3.10 Ferring BV
  • 6.3.11 Johnson & Johnson
  • 6.3.12 Merck KGaA
  • 6.3.13 Mylan N.V.
  • 6.3.14 Neurocrine Biosciences Inc.
  • 6.3.15 Novartis International AG
  • 6.3.16 Pfizer Inc.
  • 6.3.17 Sanofi SA
  • 6.3.18 Shire PLC (Takeda)
  • 6.3.19 Takeda Pharmaceutical Co. Ltd.
  • 6.3.20 Teva Pharmaceutical Industries Ltd.
  • 6.3.21 Organon & Co.
  • 6.3.22 Gedeon Richter PLC
  • 6.3.23 Novo Nordisk A/S

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment